News

Bristol-Myers deepens CMO deal with Samsung

Piggybacking off an earlier deal, Bristol-Myers Squibb has signed another manufacturing agreement with South Korean giant Samsung. 

Big Pharma megadeals could spell trouble for CROs

When Big Pharma execs talk up "synergies" to convince shareholders to buy into mergers, they mean, in part, consolidating contractors. And, with all the megadeals rumored and real surfacing over the past week, CROs could be in for a revenue haircut as the drug business realigns.

Catalent ticks up revenue as IPO pends

Global contractor Catalent swung to a profit last quarter thanks to a slight sales increase and some ongoing restructuring, staying the course as it plans to go public in an IPO worth $100 million or more.

Harlan picks a partner and expands in Southeast Asia

Toxicology specialist Harlan Laboratories is looking to tap the growing market for contract research in Oceania, signing a deal with local outfit Invenium Pharmacology to do so.

Medidata's sales leap on spike in eClinical demand

Cloud-based eClinical outfit Medidata swung to 21% revenue growth in the first quarter, and, after hitting a record value in billings, the New York company is expecting sales to keep rolling in 2014.

Biogen and Quintiles ink a deep-seated deal to boost R&D efficiency

Going well beyond the standard sponsor-CRO relationship, Biogen Idec has recruited Quintiles to revamp its clinical development process, giving the contractor a seat at the R&D table to improve trial efficiency.

Theorem deepens its ties with Medidata

CRO Theorem Clinical Research has expanded its partnership with eClinical provider Medidata, tapping technology that will allow it to capture data directly from patients.

WuXi poaches an AstraZeneca exec to amp up Chinese R&D

Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.

Quintiles taps OmniComm for early-stage data management

Global CRO Quintiles is reaching out to software provider OmniComm to replace its Phase I eClinical technology, signing a 5-year deal with the Florida company.

AMRI plans to shutter an R&D shop to save cash

Contract drug developer AMRI will close down its Syracuse, NY, facility by midyear, part of an effort to cut costs and realign its business.

InVentiv signs up to get IntelliCell's regenerative drug into the clinic

CRO inVentiv Health is teaming up with IntelliCell BioSciences to get the biotech's regenerative medicine candidate through the IND stage, pitching in to develop a novel treatment for osteoarthritis of the knee.

Certara buys Synchrogenix with its eye on regulatory writing

Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share.

CROs are spending more on merit raises, survey says

On the whole, the CRO industry is increasing its budgets for merit-based pay increases, according to a survey.

Catalent inks a biosimilar alliance with a Chinese drugmaker

Catalent has signed a deal to lend its biologics development technology to China's Zhejiang Hisun Pharmaceuticals and help the drugmaker get working on copies of some top-selling drugs.

Pacira picks Patheon to hit the gas on pain drug production

Pacira Pharmaceuticals is counting on an expanded indication and swell in demand for its surgical pain treatment, and the biotech has inked a deal with contract manufacturer Patheon to collaborate on production in a multiyear agreement.

Bristol-Myers enlists DKSH to push its drugs in Asia

Bristol-Myers Squibb is re-upping with market-access outfit DKSH to dial up its commercialization efforts in Asia, extending a deal signed in 2010.

Parexel amps up its imaging focus in rebranded informatics biz

Parexel International is looking to scale up its capabilities in medical imaging for clinical trials, expanding its eClinical outfit and appointing an industry veteran to steer the way.

Clinipace cozies up to Karyopharm to get its pipeline moving

Clinipace has signed a far-reaching deal with biotech Karyopharm, agreeing to handle a host of studies under a preferred provider arrangement.

Charles River wraps up $179M deal for Galapagos' CRO biz

Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.

Evotec lands two more deals to share risks and rewards of R&D

Germany's Evotec subverts the traditional CRO model by cozying up to its development partners with risk-splitting deals, and the company's approach to R&D has attracted Debiopharm and Convergence Pharmaceuticals with programs in cancer and chronic pain.